SHOPPING BASKET: 0 item(s) - £0.00  

You have no items in your shopping cart.


At St John’s Laboratory we are deeply passionate about advancing medical research. That’s why we are collaborating with 3 charities which fund world-class research focussed on finding treatments and cures for some of the most debilitating diseases faced by mankind. For each purchase you make, £1 of our profit will go towards your selected charity out of :

  1. JDRF ‘the type 1 diabetes charity’
  2. Alzheimer’s Research UK
  3. The Pro Cancer Research Fund

To find out more about each charity please see their bios below.

JDRF is the type 1 diabetes charity, improving lives until we find the cure.

We fund research to cure, treat and prevent type 1 diabetes. We provide information for children, adults and parents living with the condition, at all stages from diagnosis and beyond. We give a voice to people with type 1 diabetes and campaign for increased focus on, and funding for, research to find the cure.

We’re totally focused on type 1 diabetes, and are run by people with type 1, for people with type 1. JDRF is a global organisation working towards the cure. Internationally, we are the world’s leading charitable funder of type 1 diabetes research. We work with academia, industry and governments to make sure that the research we fund has the greatest possible impact on the lives of people with type 1 now and in the future.

Join us in finding the cure for type 1 diabetes. Visit for more information.

Alzheimer’s Research UK - the UK’s leading research charity aiming to defeat dementia.

Alzheimer’s Research UK powers world class studies that give us the best chance of beating dementia sooner. Our pioneering work focuses on prevention, treatment and cure and we are energising a movement across society to support, fund and take part in dementia research. We aim to empower people across all generations through greater understanding of dementia.

Dementia is caused by complex brain diseases and we're supporting the most pioneering science to discover what causes nerve cells to die and why. Our  research projects  and Stem Cell Research Centre  are examples of how we're innovating research to defeat dementia. We put these discoveries to work to benefit people with dementia. Through big initiatives like our  Drug Discovery Alliance Dementia Consortium Global Clinical Trials Fund  and  Prevention Fund , we're translating these findings into new treatments and preventions that can change lives. Through our  Research Network  and global partnerships, we're supporting the best minds and resources to create the world's leading dementia research field.

To join the fight, please visit Together we have the power to defeat dementia.

Pro Cancer Research Fund – Neuroscience Solutions to Cancer.

PCRF is developing a novel approach to understanding and treating cancer. Cancer is a complex disease, like a ‘pathological universe’! The cancer research supported by PCRF is unique, originating from 25 years of experience on the brain, a ‘biological universe’. Hence, we call it “ neuroscience solutions to cancer. ” Every cell in the human body has some electrical activity, most readily seen as the electrocardiogram of a beating heart.

PCRF scientists were first to question whether electrical signalling played a part in metastasis, the spreading of cancer and the main cause of death in cancer patients. It was discovered that in order to metastasise cancer cells express a “voltage-gated sodium channel” (VGSC) at a high level and thus become excitable, rather like neurons in an epileptic brain. In other words, it is this excitability that makes metastatic cancer cells hyperactive and aggressive. Such cells disrupt and invade their surroundings and once they hit a blood or lymph vessel and get into the circulation, they can spread around the body and disrupt various vital organs. Blocking this channel using drugs or genetically suppresses the cells’ invasiveness. The phenomenon has been confirmed to occur in cancers of breast, prostate, colon, lung, cervix and ovary. The VGSC is integral to the metastatic process and has important characteristics that would make it an ideal target for attacking cancer. First, it is expressed very early in the metastatic process and since early detection will save lives, it gives an indication of how the cancer will progress thereby facilitating the decision making regarding surgery and/or appropriate therapy. Second, it can be blocked with drugs that are not toxic. So, VGSC-based therapies will be ‘targeted’ without any of the debilitating side effects of treatments like chemotherapy.